Study #2021-0442
Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide,and Dexamethasone vs Carfilzomib, Lenalidomide,and Dexamethasone vs Bortezomib, Lenalidomide,and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)
MD Anderson Study Status
Not Accepting
Treatment Agent
Bortezomib, Dexamethasone, Lenalidomide, Autologous Stem Cell Transplant (ASCT), Carfilzomib, Acetaminophen, Diphenhydramine, Montelukast, Daratumumab
Description
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Phase II
Physician name:
Jing Ye
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.